Mark J. Vignola - 01 Feb 2023 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Chief Financial Officer
Signature
/s/ Bryan Yoon, as Attorney-in-Fact for Mark J. Vignola
Issuer symbol
TERN
Transactions as of
01 Feb 2023
Net transactions value
+$4.23
Form type
4
Filing time
03 Feb 2023, 17:01:08 UTC
Previous filing
08 Jun 2022
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Purchase $4.23 +3 +0.04% $1.41* 7,659 30 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Award $0 +360,000 $0.000000 360,000 01 Feb 2023 Common Stock 360,000 $8.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes the purchase of 3 shares under the Terns Employee Stock Purchase Plan on November 30, 2022.
F2 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Includes voluntary reporting of ESPP purchase